HPV-ASSOCIATED CERVICAL DISEASES IN WOMEN WITH AUTOIMMUNE DISEASES: VACCINATION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To carry out a systematic analysis of the data available in the modern literature on HPV-associated diseases in women with systemic lupus erythematosus and on possible primary prevention in them. Materials and methods. The review included the data of foreign and Russian papers published in the past 8 years and found in Pubmed on this topic. Results. The paper shows data on the incidence of HPV infection and HPV-associated cervical diseases in women with immunodeficiency states. It presents the possibilities of primary prevention of HPV infection in patients with systemic lupus erythematosus. Conclusion. There is a need for further investigations of the prevalence and prevention of possible complications due to HPV infection in women with systemic lupus erythematosus.

Full Text

Restricted Access

About the authors

Vera Nikolaevna Prilepskaya

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: vprilepskaya@mail.ru
MD, PhD, Professor, Deputy Director for Science Moscow 117997, Ac. Oparina str. 4, Russia

Anna Nersesovna Mgeryan

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: docanna@mail.ru
Ph.D., researcher Moscow 117997, Ac. Oparina str. 4, Russia

Niso Mirzoevna Nazarova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: grab2@yandex.ru
MD, PhD, Senior Researcher Moscow 117997, Ac. Oparina str. 4, Russia

Marina Nesterovna Kostava

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: kolposkop@mail.ru
MD, physician Moscow 117997, Ac. Oparina str. 4, Russia

References

  1. Santana I.U., Gomes Ado N., Lyrio L.D., Rios Grassi M.F., Santiago M.B. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin. Rheumatol. 2011; 30(5): 665-72.
  2. Прилепская В.Н., Назарова Н.М., Суламанидзе Л.А., Бурменская О.В., Трофимов Д.Ю., Павлович С.В. Заболевания аногенитальной области, ассоциированные с паппиломавирусной инфекцией. Гинекология. 2015; 17(1): 4-7.
  3. Shukla S., Bharti A.C., Mahata S., Hussain S., Kumar R., Hedau S., Das B.C. Infection of human papillomaviruses in cancers of different human organ sites. Indian J. Med. Res. 2009; 130(3): 222-33.
  4. Grm H.S., Bergant M., Banks L. Human papillomavirus infection, cancer and therapy. Indian J. Med. Res. 2009; 130(3): 277-85.
  5. Hsueh P.R. Human papillomavirus, genital warts, and vaccines. J. Microbiol. Immunol. Infect. 2009; 42(2): 101-6.
  6. Lyrio L.D., Grassi M.F., Santana I.U., Olavarria V.G., Gomes Ado N., Costa Pinto L. et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol. Int. 2013; 33(2): 335-
  7. Mercado U. Squamous intraepithelial lesions in women’s lupus. Ginecol. Obstet. Méx. 2009; 77(9): 423-7.
  8. Tam L.S., Chan P.K., Ho S.C., Yu M.M., Yim S.F., Cheung T.H. et al. Natural history of cervical papilloma virus infection in systemic lupus erythematosus-a prospective cohort study. J. Rheumatol. 2010; 37(2): 330-40.
  9. Abud-Mendoza C., Cuevas-Orta E., Santillân-Guerrero E.N., Martinez-Martinez M.U., Hernández-Castro B., Estrada-Capetillo L. et al. Decreased blood levels of B lymphocytes and NK cells in patients with systemic lupus erythematosus (SLE) infected with papillomavirus (HPV). Arch. Dermatol. Res. 2013; 305(2): 117-23.
  10. Bernatsky S., Ramsey-Goldman R., Clarke A.E. Malignancy in systemic lupus erythematosus: what have we learned? Best Pract. Res. Clin. Rheumatol. 2009; 23(4): 539-47.
  11. Klumb E.M., Araujo M.L. Jr., Jesus G.R., Santos D.B., Oliveira A.V., Albuquerque E.M., Macedo J.M. Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression? J. Clin. Rheumatol. 2010; 16(4): 153-7.
  12. Febronio M.V., Pereira R.M., Bonfa E., Takiuti A.D., Pereyra E.A., Silva C.A. Inflammatory cervicovaginal cytology is associated with disease activity in juvenile systemic lupus erythematosus. Lupus. 2007; 16(6): 430-5.
  13. Zard E., Arnaud L., Mathian A., Chakhtoura Z., Hie M., Touraine P. et al. Increased risk of grade cervical squamosus intraepithelial lesions in systemic lupus erythemasosus: a meta-analysis of the literature. Autoimm. Rev. 2014; 13(7): 730-5.
  14. Dreyer L., Faurschou M., Mogensen M., Jacobsen S. High incidence of potentially virus-induced malignancies in systemic lupus erythemasosus:a long-term followup study in a Danish cohort. Arthritis Rheum. 2011; 63(10): 3032-7.
  15. Soybilgic A., Onel K.B., Utset T., Alexander K., Wagner-Weiner L. Safety and immunogenicity of the quadrivalent HPV vaccine in female systemic lupus erythematosus patients aged 12 to 26 years. Pediatr. Rheumatol. Online J. 2013; 11: 29.
  16. Bernatsky S., Boivin J.F., Joseph L., Rajan R., Zoma A., Manzi S. et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 2005; 52(5): 1481-90.
  17. Nived O., Sturfelt G., Bengtsson A.A. Improved lupus outcome. We are doing a good job, but could we do better. J. Rheumatol. 2008; 35(11): 2088-9.
  18. Parikh-Patel A., White R.H., Alien M., Cress R. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control. 2008; 19(8): 887-94.
  19. Kim S.C., Glynn R.J., Giovannucci E., Hernández-Díaz S., Liu J., Feldman S. et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann. Rheum. Dis. 2015; 74(7): 1360-7.
  20. Skare T.L., da Rocha B.V. Breast and cervical cancer in patients with systemic lupus erythematosus. Rev. Bras. Ginecol. Obstet. 2014; 36(8): 367-71.
  21. Rojo-Contreras W., Olivas-Flores E.M., Gamez-Nava J.I., Montoya-Fuentes H., Trujillo-Hernandez B., Trujillo X. et al. Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. Lupus. 2012; 21(4): 365-72.
  22. Abdel-Rahman M.E., Butler J., Sydes M.R., Parmar M.K., Gordon E., Harper P. et al. No socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials. Br. J. Cancer. 2014; 111(3): 589-97.
  23. Suszek D., Jeleniewicz R., Majdan M. Neoplasia in patients with systemic lupus erythematosus: analysis of two cases of hematological malignancies. Ann. Acad. Med. Stetin. 2011; 57(3): 28-31.
  24. Kang K.Y., Kim H.O., Yoon H.S., Lee J., Lee W.C., Ko H.J. et al. Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin. Rheumatol. 2010; 29(4): 381-8
  25. Bosch F.X., Burchell A.N., Schiffman M., Giuliano A.R., de Sanjose S., Bruni L. et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia.Vaccine. 2008; 26(Suppl. 10): K1-16.
  26. Dey D., Kenu E., Isenberg D.A. Cancer complicating systemic lupus erythematosus-a dichotomy emerging from a nested case-control study. Lupus. 2013; 22(9): 919-27.
  27. Tani C., Carli L., Mosca M., Baldini C., Consensi A., Doveri M. et al. Adherence to cervical cancer screening in an Italian SLE cohort. Reumatismo. 2011; 63(1): 11-7.
  28. World Health Organization. Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals. Accessed January 13, 2013.
  29. Stowe J., Andrews N., Wise L., Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenza-like illness using the United Kingdom General Practice Research Database. Am. J. Epidemiol 2009; 169(3): 382-8.
  30. Balofsky A., Agmon-Levin N., Shoenfeld Y. The new H1N1 and HPV vaccines and old fears. Curr. Opin. Rheumatol. 2010; 22(4): 431-6.
  31. Harper D.M. Currently approved prophylactic HPV vaccines. Expert Rev. Vaccines. 2009; 8(12): 1663-79.
  32. Grimaldi-Bensouda L., Aubrun E., Leighton P., Benichou J., Rossignol M., Abenhaim L.; PGRx Study Group. Agreement between patients’ self-report and medical records for vaccination: the PGRx database. Pharmacoepidemiol. Drug Saf. 2013; 22(3): 278-85.
  33. Heijstek M., Scherpenisse M., Groot N., Tacke C., Schepp R.M., Buisman A.M. et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann. Rheum. Dis. 2014; 73(8): 1500-7.
  34. Soybilgic A., Onel K.B., Utset T., Alexander K., Wagner-Weiner L. Safety and immunogenicity of the quadrivalent HPV vaccine in female systemic lupus erythematosus patients aged 12 to 26 years. Pediatr. Rheumatol. Online J. 2013; 11: 29.
  35. Mok C.C., Ho L.Y., Fong L.S., To C.H. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann. Rheum. Dis. 2013; 72(5): 659-64.
  36. Pellegrino P., Carnovale C., Perrone V., Salvati D., Gentili M., Antoniazzi S. et al. Human papillomavirus vaccine in patients with systemic lupus erythematosus. Epidemiology. 2014; 25(1): 155-6.
  37. Petäjä T., Pedersen C., Poder A., Strauss G., Catteau G., Thomas F. et al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-aduvanted vaccine in preteen/adolescent girls and young women. Int. J. Cancer. 2011; 129(9): 2147-57.
  38. Block S.L., Brown D.R., Chatterjee A., Gold M.A., Sings H.L., Meibohm A. et al. Clinical trial and postlicensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr. Infect. Dis. J. 2010; 29(2): 95-101.
  39. Slade B.A., Leidel L., Vellozzi C., Woo E.J., Hua W., Sutherland A. et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009; 302(7): 750-7.
  40. Chao C., Klein N.P., Velicer C.M., Sy L.S., Slezak J.M., Takhar H. et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J. Intern. Med. 2012; 271(2): 193-203.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies